ESCMID Global 2025: Sex differences in patients with serious bacterial infections
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference held in Vienna, Austria from 11 …
Post
-
-
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels …
-
ESCMID Global 2025: The challenges of eliminating viral hepatitis
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, held from 11 …
-
ESCMID Global 2025: The challenges of eliminating viral hepatitis
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, held from April …
-
WHO warns that polio cases are on the rise
The World Health Organization (WHO) has released an update on polio following the March 2025 meeting of the International Health …
-
Northwestern University enrols first subject in trial of drug for pericarditis
Northwestern University in Illinois, US, has enrolled the first subject in a Phase III trial of Cardiol Therapeutics' drug candidate, …
-
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial
The European Medicines Agency (EMA) has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid …
-
Sabin Vaccine Institute begins trial of vaccine candidate for Marburg virus disease
The Sabin Vaccine Institute has begun a Phase II trial in the US to evaluate its Marburg vaccine, with the …
-
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical …
-
Podcast: What’s next for the pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans …
-
Analysis tracks condition of patients recovered from Omicron Covid-19 infection
Among the myriad strains of Covid-19 infection that have emerged since the outset of the pandemic, variants branching from the …
-
Hoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritus
US-based biopharmaceutical company Hoth Therapeutics has reported interim data from a Phase IIa trial of HT-001, a drug designed for …
-
FDA clears eGenesis’ genetically engineered porcine liver for Phase I trial
eGenesis has gained US Food and Drug Administration (FDA) clearance on an investigational new drug (IND) application for a genetically …
-
Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours
US-based biopharmaceutical company Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral …
-
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure
An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF trial as designed. The decision …
